- Home
- XPON vs ZVSA Comparison
XPON vs ZVSA Comparison
Compare XPON & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- ZVSA
- Stock Information
- Founded
- XPON 2016
- ZVSA 2014
- Country
- XPON United States
- ZVSA United States
- Employees
- XPON 23
- ZVSA 7
- Industry
- XPON Electronic Components
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- ZVSA Health Care
- Exchange
- XPON Nasdaq
- ZVSA Nasdaq
- Market Cap
- XPON 2.3M
- ZVSA 2.6M
- IPO Year
- XPON 2022
- ZVSA N/A
- Fundamental
- Price
- XPON $2.45
- ZVSA $1.10
- Analyst Decision
- XPON
- ZVSA Strong Buy
- Analyst Count
- XPON 0
- ZVSA 1
- Target Price
- XPON N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- XPON 566.8K
- ZVSA 3.6M
- Earning Date
- XPON 11-14-2024
- ZVSA 11-14-2024
- Dividend Yield
- XPON N/A
- ZVSA N/A
- EPS Growth
- XPON N/A
- ZVSA N/A
- EPS
- XPON N/A
- ZVSA N/A
- Revenue
- XPON $4,498,181.00
- ZVSA N/A
- Revenue This Year
- XPON $0.68
- ZVSA N/A
- Revenue Next Year
- XPON $29.04
- ZVSA N/A
- P/E Ratio
- XPON N/A
- ZVSA N/A
- Revenue Growth
- XPON N/A
- ZVSA N/A
- 52 Week Low
- XPON $2.09
- ZVSA $1.04
- 52 Week High
- XPON $639.00
- ZVSA $42.35
- Technical
- Relative Strength Index (RSI)
- XPON 34.81
- ZVSA 32.04
- Support Level
- XPON $2.35
- ZVSA $1.10
- Resistance Level
- XPON $2.83
- ZVSA $1.29
- Average True Range (ATR)
- XPON 0.34
- ZVSA 0.25
- MACD
- XPON 0.01
- ZVSA -0.02
- Stochastic Oscillator
- XPON 11.33
- ZVSA 3.86
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles ("RV's") and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.